Your browser is no longer supported. Please, upgrade your browser.
Settings
XNCR Xencor, Inc. daily Stock Chart
XNCR [NASD]
Xencor, Inc.
Index- P/E50.84 EPS (ttm)0.65 Insider Own13.40% Shs Outstand56.27M Perf Week-4.17%
Market Cap1.85B Forward P/E- EPS next Y-1.97 Insider Trans0.80% Shs Float48.81M Perf Month5.46%
Income39.10M PEG- EPS next Q-0.20 Inst Own85.90% Short Float6.63% Perf Quarter2.02%
Sales152.50M P/S12.12 EPS this Y-223.50% Inst Trans0.44% Short Ratio14.47 Perf Half Y-12.59%
Book/sh10.83 P/B3.03 EPS next Y-118.80% ROA6.40% Target Price42.80 Perf Year-12.07%
Cash/sh6.05 P/C5.43 EPS next 5Y- ROE7.20% 52W Range27.75 - 48.38 Perf YTD-9.18%
Dividend- P/FCF- EPS past 5Y-17.50% ROI-15.20% 52W High-32.12% Beta1.30
Dividend %- Quick Ratio6.70 Sales past 5Y31.90% Gross Margin- 52W Low18.34% ATR1.55
Employees156 Current Ratio6.70 Sales Q/Q- Oper. Margin19.30% RSI (14)49.74 Volatility4.10% 4.52%
OptionableYes Debt/Eq0.02 EPS Q/Q323.40% Profit Margin25.60% Rel Volume0.59 Prev Close32.98
ShortableNo LT Debt/Eq0.02 EarningsMay 09 AMC Payout0.00% Avg Volume223.69K Price32.84
Recom1.70 SMA20-0.02% SMA502.37% SMA200-8.31% Volume132,805 Change-0.42%
Apr-12-19Initiated Guggenheim Buy
Mar-27-19Initiated Berenberg Buy $45
Mar-15-19Initiated Raymond James Outperform
Sep-10-18Resumed BTIG Research Buy $56
Mar-28-18Resumed Leerink Partners Outperform $36
Mar-02-17Reiterated Wedbush Outperform $27 → $33
Mar-02-17Initiated Instinet Neutral $21
Oct-04-16Initiated Piper Jaffray Overweight
Dec-22-15Initiated Canaccord Genuity Buy $20
Aug-05-15Reiterated MLV & Co Buy $22 → $29
Feb-12-15Reiterated Oppenheimer Outperform $22 → $28
Jan-28-15Reiterated MLV & Co Buy $18 → $22
Jul-11-14Initiated Oppenheimer Outperform $22
May-23-19 08:01AM  Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development Business Wire
May-15-19 12:14PM  Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-10-19 09:23AM  Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript Motley Fool +10.31%
May-09-19 04:43PM  Xencor: 1Q Earnings Snapshot Associated Press
04:00PM  Xencor Reports First Quarter 2019 Financial Results Business Wire
May-08-19 04:01PM  Xencor to Present at Upcoming Investor Conferences Business Wire
May-06-19 08:01AM  Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors Business Wire
May-02-19 04:01PM  Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019 Business Wire
May-01-19 01:22PM  Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount? Simply Wall St.
Apr-30-19 08:01AM  Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045 Business Wire
Apr-29-19 09:55PM  Heres What Hedge Funds Think About Xencor Inc (XNCR) Insider Monkey
Apr-02-19 08:01AM  Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program Business Wire
Apr-01-19 04:05PM  Xencor to Participate in Upcoming Investor Conferences Business Wire
12:55PM  Why I Like Xencor, Inc. (NASDAQ:XNCR) Simply Wall St.
Mar-08-19 08:01AM  Xencor Announces Closing of Research Collaboration and License Agreement with Genentech Business Wire
Mar-06-19 07:00AM  New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-01-19 12:30PM  Is Xencor, Inc.s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers? Simply Wall St.
06:18AM  Edited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 09:15AM  Too Much Talking, Not Enough Action Zacks
Feb-26-19 09:48PM  Xencor Inc (XNCR) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
09:11AM  Nielsen (NLSN) to Report Q4 Earnings: What's in the Offing? Zacks
Feb-25-19 09:05PM  Xencor Inc (XNCR) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:24PM  Xencor Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
02:30PM  Xencor, Inc. to Host Earnings Call ACCESSWIRE
09:12AM  What's in Store for Booking Holdings' (BKNG) Q4 Earnings? Zacks
Feb-23-19 09:15AM  Strong Friday Close Secures a 9th Week in the Green Zacks
Feb-20-19 06:55AM  Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045 PR Newswire -6.54%
Feb-19-19 09:01AM  Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019 PR Newswire
Feb-07-19 09:01AM  Xencor to Present at Upcoming Investor Conferences PR Newswire
Feb-05-19 08:01AM  Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech PR Newswire
Jan-28-19 07:35AM  Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-21-19 06:12AM  Have Insiders Been Selling Xencor, Inc. (NASDAQ:XNCR) Shares This Year? Simply Wall St.
Jan-07-19 08:01AM  Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody PR Newswire
Dec-06-18 10:45AM  Is Xencor Inc (NASDAQ:XNCR) A Financially Strong Company? Simply Wall St.
Dec-04-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage Fundamental Analysis, Key Performance Indications GlobeNewswire -6.28%
Dec-03-18 05:45PM  Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire
Nov-20-18 09:01AM  Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-08-18 09:01AM  Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors PR Newswire
Nov-06-18 05:40PM  Edited Transcript of XNCR earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents +6.83%
05:06AM  Xencor: 3Q Earnings Snapshot Associated Press
Nov-05-18 04:01PM  Xencor Reports Third Quarter 2018 Financial Results PR Newswire
Nov-01-18 09:01AM  Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire +15.59%
Oct-30-18 10:33AM  Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline Zacks
Oct-29-18 04:01PM  Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018 PR Newswire -5.69%
Oct-25-18 08:50AM  Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.86%
Oct-05-18 08:01AM  Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting PR Newswire
Sep-25-18 08:01AM  Xencor to Participate in Upcoming Investor Conferences PR Newswire -5.47%
Sep-18-18 06:32AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Aug-08-18 08:30AM  New Research Coverage Highlights Goldman Sachs BDC, PTC, Weingarten Realty Investors, Astronics, Xencor, and Chemours Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-07-18 04:50PM  This Midcap Biotech Popped Nearly 20% On Hope In Cancer, Inflammation Investor's Business Daily +7.49%
Aug-06-18 05:45PM  Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:41PM  Xencor: 2Q Earnings Snapshot Associated Press
04:01PM  Xencor Reports Second Quarter 2018 Financial Results PR Newswire
02:30PM  Xencor, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:01AM  Xencor to Present at Upcoming Investor Conferences PR Newswire
Jul-30-18 08:01AM  Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018 PR Newswire
Jul-18-18 06:00AM  Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors PR Newswire
Jul-16-18 08:20AM  Today's Research Reports on Trending Tickers: REGENXBIO and Xencor ACCESSWIRE
Jul-12-18 04:00PM  Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors PR Newswire
Jun-18-18 11:45AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-31-18 04:01PM  Xencor to Present at Upcoming Investor Conferences PR Newswire
May-09-18 03:56PM  Edited Transcript of XNCR earnings conference call or presentation 7-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-07-18 04:19PM  Xencor: 1Q Earnings Snapshot Associated Press
04:01PM  Xencor Reports First Quarter 2018 Financial Results PR Newswire
12:30PM  Xencor, Inc. to Host Earnings Call ACCESSWIRE
May-04-18 07:55AM  Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-02-18 08:00AM  Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference PR Newswire
Apr-30-18 08:00AM  Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018 PR Newswire
Apr-18-18 09:00AM  Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting PR Newswire
Apr-11-18 06:31PM  What Do Analysts Think About Xencor Incs (NASDAQ:XNCR) Earnings Trajectory? Simply Wall St.
01:46PM  Harry Boxers five biotech stocks to watch MarketWatch
Apr-04-18 09:15PM  3 Top Biotech Stocks to Buy in April Motley Fool
Mar-30-18 03:21PM  Edited Transcript of XNCR earnings conference call or presentation 27-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-21-18 08:00AM  Xencor to Present at 17th Annual Needham Healthcare Conference PR Newswire
Mar-20-18 07:44PM  Xencor Announces Pricing of Public Offering of Common Stock PR Newswire
Mar-19-18 04:09PM  Xencor, Inc. Announces Proposed Public Offering of Common Stock PR Newswire
Mar-03-18 04:43PM  What Do Investors Need To Know About Xencor Incs (NASDAQ:XNCR) Growth? Simply Wall St.
Mar-01-18 08:30AM  Consolidated Research: 2018 Summary Expectations for Sonic Automotive, Xencor, Gevo, OSI, Buckeye Partners, and Glatfelter Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-27-18 06:27PM  Xencor reports 4Q loss Associated Press
04:01PM  Xencor Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
12:40PM  Xencor, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-18 08:00AM  Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors PR Newswire +5.01%
Feb-20-18 08:00AM  Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018 PR Newswire
Feb-07-18 08:00AM  Xencor to Present at Upcoming Investor Conferences PR Newswire
Jan-05-18 08:00AM  Xencor Announces 2018 Priorities and Expected Milestones PR Newswire
07:45AM  New Research: Key Drivers of Growth for Portola Pharmaceuticals, Kindred Healthcare, Interface, Apogee Enterprises, Sonic Automotive, and Xencor Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Dec-28-17 12:46PM  ETFs with exposure to Xencor, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:40AM  Xencor, Inc. :XNCR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-19-17 08:00AM  Xencor Appoints Richard Ranieri to Board of Directors PR Newswire
Dec-14-17 02:48PM  Xencor, Inc. Value Analysis (NASDAQ:XNCR) : December 14, 2017 Capital Cube
Dec-13-17 07:42AM  Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : December 13, 2017 Capital Cube
Dec-05-17 08:00AM  Xencor Receives Milestone Payment from Amgen PR Newswire
Nov-27-17 08:07AM  Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : November 27, 2017 Capital Cube
08:05AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Nov-15-17 08:04AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Nov-13-17 02:16PM  Edited Transcript of XNCR earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-10-17 08:16AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit +5.36%
Nov-08-17 08:00AM  Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting PR Newswire
Nov-07-17 05:14PM  Xencor reports 3Q loss Associated Press
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STAFFORD JOHN S III10% OwnerMay 02Buy29.8714,611436,4075,077,359May 06 04:06 PM
STAFFORD JOHN S III10% OwnerMar 25Buy29.773,500104,1955,062,748Mar 26 04:32 PM
STAFFORD JOHN S III10% OwnerMar 22Buy29.962,00059,9205,059,248Mar 26 04:32 PM
STAFFORD JOHN S III10% OwnerMar 18Buy29.901,10032,8905,057,248Mar 19 05:04 PM
STAFFORD JOHN S III10% OwnerMar 15Buy29.0238,3001,111,4665,056,148Mar 19 05:04 PM
Foster Paul AChief Medical OfficerSep 17Option Exercise11.0540,000442,00044,952Sep 18 04:28 PM
Foster Paul AChief Medical OfficerSep 17Sale46.0340,0001,841,2084,952Sep 18 04:28 PM
STAFFORD JOHN S III10% OwnerSep 14Sale48.051,00048,0545,017,848Sep 18 04:04 PM
Foster Paul AChief Medical OfficerAug 17Option Exercise11.053,65940,4328,611Aug 17 06:20 PM
Foster Paul AChief Medical OfficerAug 17Sale40.103,659146,7264,952Aug 17 06:20 PM
Foster Paul AChief Medical OfficerAug 16Option Exercise11.0520,739229,16625,691Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 16Sale41.1020,739852,3734,952Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 15Option Exercise11.051061,1715,058Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 15Sale41.101064,3574,952Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 14Option Exercise11.0515,496171,23120,448Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 14Sale41.1115,496636,9804,952Aug 16 07:31 PM
Baracchini Edgardo JrChief Business OfficerAug 13Option Exercise11.0512,734140,71112,941Aug 13 07:59 PM
Baracchini Edgardo JrChief Business OfficerAug 13Sale40.3512,734513,874207Aug 13 07:59 PM
Baracchini Edgardo JrChief Business OfficerAug 10Sale40.0328,9831,160,045207Aug 13 07:59 PM
Desjarlais John RSr. V.P., Research & CSOAug 10Sale40.0314,867595,09288,098Aug 10 06:36 PM
Desjarlais John RSr. V.P., Research & CSOAug 09Option Exercise4.2535,000148,750123,098Aug 10 06:36 PM
Baracchini Edgardo JrChief Business OfficerAug 09Option Exercise11.0537,266411,78937,473Aug 13 07:59 PM
Baracchini Edgardo JrChief Business OfficerAug 09Sale40.358,283334,19829,190Aug 13 07:59 PM
Desjarlais John RSr. V.P., Research & CSOAug 09Sale40.6120,133817,629102,965Aug 10 06:36 PM
STAFFORD JOHN S III10% OwnerJul 17Sale41.2436,5001,505,2605,018,848Jul 17 04:08 PM
STAFFORD JOHN S III10% OwnerJul 16Sale40.6726,8881,093,5355,055,348Jul 17 04:08 PM
STAFFORD JOHN S III10% OwnerJul 13Sale41.9748,3122,027,6845,082,236Jul 17 04:08 PM
STAFFORD JOHN S III10% OwnerJul 12Sale39.5558,0002,293,9005,130,548Jul 12 05:26 PM
STAFFORD JOHN S III10% OwnerJul 11Sale39.6330,0071,189,1775,188,548Jul 12 05:26 PM
STAFFORD JOHN S III10% OwnerJul 10Sale39.8950,2932,006,1885,218,555Jul 12 05:26 PM
STAFFORD JOHN S III10% OwnerJun 20Sale40.0592,7793,715,7995,261,348Jun 20 04:28 PM
STAFFORD JOHN S III10% OwnerJun 19Sale39.77103,4544,114,3665,354,127Jun 20 04:28 PM
STAFFORD JOHN S III10% OwnerJun 18Sale39.8853,7672,144,2285,457,581Jun 20 04:28 PM
Dahiyat Bassil IPresident and CEOJun 15Option Exercise4.2550,000212,500343,067Jun 15 08:11 PM
Dahiyat Bassil IPresident and CEOJun 15Sale40.5150,0002,025,690293,067Jun 15 08:11 PM
Kuch John JSr. Vice President & CFOJun 13Option Exercise4.2535,853152,37592,482Jun 15 05:35 PM
Kuch John JSr. Vice President & CFOJun 13Sale41.6425,0001,040,94556,629Jun 15 05:35 PM